HIV/HBV Coinfection
CROI 2013: Dually Active Antiretroviral Therapy Protects Against Primary Hepatitis B Infection
- Details
- Category: HBV Treatment
- Published on Wednesday, 06 March 2013 00:00
- Written by Liz Highleyman
Use of antiretroviral therapy (ART) that includes drugs active against both hepatitis B virus (HBV) and HIV reduces the risk that HIV positive people will become infected with HBV -- in effect acting as HBV PrEP -- according to a study presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this week in Atlanta.
Coverage of the 2013 Conference on Retroviruses and Opportunistic Infections
- Details
- Category: HIV Treatment
- Published on Monday, 04 March 2013 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), March 3-6, 2013, in Atlanta.
Conference highlights include HIV experimental therapies and treatment strategies, HIV cure research, HIV-related conditions and complications, treatment as prevention and PrEP, new treatments for hepatitis C, and HIV/HBV and HIV/HCV coinfection.
HIVandHepatitis.com CROI 2013 conference section
3/4/13
Tenofovir plus Emtricitabine or Lamivudine Does Not Always Suppress Hepatitis B in HIV/HBV Coinfected
- Details
- Category: HIV/HBV Coinfection
- Published on Thursday, 28 February 2013 00:00
- Written by Liz Highleyman
HIV/HBV coinfected people with high hepatitis B virus (HBV) levels and those who are HBeAg positive are at greater risk of not achieving HBV suppression after a year on tenofovir plus emtricitabine or lamivudine, but most did so eventually, researchers reported in the February 21, 2013, advance online edition of AIDS.
CROI 2013: Retrovirus Conference Starts Sunday in Atlanta
- Details
- Category: HIV Treatment
- Published on Thursday, 28 February 2013 00:00
- Written by Liz Highleyman
The 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) kicks off Sunday, March 3, at the Georgia World Congress Center in Atlanta. HIVandHepatitis.com will be on site next week to bring you breaking news coverage on HIV and hepatitis C.
Look for reports from the HIVandHepatitis.com team and our content partners at NAM/Aidsmap.com starting Monday. Sign up for our email newsletter to get the latest headlines and follow us on Twitter @HIVandHepatitis.
FDA: Do Not Mix Hepatitis B Drug Adefovir with Stribild HIV Combo Pill
- Details
- Category: Drug Advisories & Warnings
- Published on Tuesday, 04 December 2012 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) last week announced an update to the label information for adefovir dipivoxil (Hepsera), adding the 4-in-1 antiretroviral combination pill Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) to the list of other products that should not be co-administered with adefovir.
Web Design and Development by